Get started
Author

Zachary William Neil Veitch

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies
2022 · John Hilton, Karen Gelmon, et al. · Nature Communications · 167
PDF
Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance
2008 · Stacey L Hembruff, Monique L Laberge, et al. · BMC Cancer · 87
PDF
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial
2019 · Zachary W. Veitch, David W. Cescon, et al. · British Journal of Cancer · 73
PDF
Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials
2021 · Zachary W Veitch, Daniel Shepshelovich, et al. · JNCI Journal of the National Cancer Institute · 62
cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance
2005 · David J. Villeneuve, Stacey L. Hembruff, et al. · Breast Cancer Research and Treatment · 58
Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance
2009 · Zachary W. Veitch, Baoqing Guo, et al. · Pharmacogenetics and Genomics · 57
Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay
2025 · Mitchell J. Elliott, Philippe Echelard, et al. · Nature Communications · 45
PDF
Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer
2019 · Zachary Veitch, Omar F. Khan, et al. · Journal of the National Comprehensive Cancer Network · 42
PDF
Acceptability of Routine Evaluations Using Patient-Reported Outcomes of Common Terminology Criteria for Adverse Events and Other Patient-Reported Symptom Outcome Tools in Cancer Outpatients: Princess Margaret Cancer Centre Experience
2019 · Hamzeh Albaba, Tristan A. Barnes, et al. · The Oncologist · 22
PDF
Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells
2007 · Amadeo M. Parissenti, Stacey L. Hembruff, et al. · Anti-Cancer Drugs · 21
Abstract OT1-08-04: A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors
2020 · Dejan Juric, Kevin Kalinsky, et al. · Cancer Research · 19
A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events
2023 · Helena J. Janse van Rensburg, Zhihui Liu, et al. · British Journal of Cancer · 16
PDF
Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE
2022 · Geoffrey A. Watson, Zachary W. Veitch, et al. · British Journal of Cancer · 16
No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer
2021 · Zachary Veitch, Domen Ribnikar, et al. · British Journal of Cancer · 13
Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+/HER2- breast cancer
2020 · Komal Jhaveri, Kevin Kalinsky, et al. · Cancer Research · 11
A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS)
2019 · Zachary Veitch, Alona Zer, et al. · Scientific Reports · 11
PDF
Abstract CT109: A phase I/Ib study evaluating GDC-0077 plus fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive/HER2-negative breast cancer
2020 · Kevin Kalinsky, Dejan Juric, et al. · Cancer Research · 10
Incorporating Genomics Into the Care of Patients With Advanced Breast Cancer
2018 · Jeremy Kratz, Mark Burkard, et al. · American Society of Clinical Oncology Educational Book · 10
The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy
2022 · Husam A. Alqaisi, Carlos Stecca, et al. · Therapeutic Advances in Medical Oncology · 9
Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study
2021 · Esmail M. Al-ezzi, Zachary W. Veitch, et al. · PLoS ONE · 6
PDF
Abstract PS06-08: Longitudinal Neoadjuvant and Post-operative Evaluation of Circulating Tumor DNA in Early Breast Cancer using a Tumor-Informed Assay: Updated Analysis of the TRACER Cohort
2024 · Mitchell Elliott, Jesus Fuentes Antras, et al. · Cancer Research · 5
Clinical outcomes of non‐osteogenic, non‐Ewing soft‐tissue sarcoma of bone––experience of the Toronto Sarcoma Program
2020 · Zachary W. Veitch, Samir Fasih, et al. · Cancer Medicine · 5
PDF
Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer
2019 · Zachary Veitch, Omar F. Khan, et al. · Journal of the National Comprehensive Cancer Network · 5
PDF
Adjustments in relative dose intensity (RDI) for FECD chemotherapy in breast cancer: A population analysis.
2017 · Zachary William Neil Veitch, Omar Farooq Khan, et al. · Journal of Clinical Oncology · 5
310P Longitudinal evaluation of circulating tumour DNA in early breast cancer using a plasma-only methylation-based assay
2023 · M. Elliott, J. Fuentes Antras, et al. · Annals of Oncology · 4
PDF
Works count: 57
Citation count: 816
H-index: 13
I10-index: 18
Year
Topic
Type